Carlos M Ferrario Selected Research

Carlos M Ferrario Research Topics

Disease

54	Hypertension (High Blood Pressure) 04/2022 - 01/2002
16	Heart Failure 11/2021 - 04/2002
15	Fibrosis (Cirrhosis) 02/2020 - 09/2005
10	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 09/2005
10	Body Weight (Weight, Body) 01/2019 - 10/2002
10	Insulin Resistance 12/2013 - 02/2005
9	Heart Diseases (Heart Disease) 04/2021 - 08/2015
9	Proteinuria 04/2014 - 01/2009
9	Hypertrophy 12/2013 - 07/2005
8	Cardiomegaly (Heart Hypertrophy) 12/2019 - 05/2002
8	Inflammation (Inflammations) 01/2019 - 01/2002
8	Left Ventricular Dysfunction 02/2017 - 05/2004
7	Atherosclerosis 01/2015 - 01/2002
7	Myocardial Infarction 01/2015 - 10/2003
6	Vascular Remodeling 01/2016 - 07/2005
5	Stroke (Strokes) 04/2021 - 11/2004
5	Vascular Diseases (Vascular Disease) 11/2018 - 01/2002
4	COVID-19 01/2021 - 01/2020
4	Atrial Fibrillation 08/2020 - 01/2011
4	Ventricular Remodeling 01/2020 - 10/2005
3	Essential Hypertension 01/2021 - 12/2007
3	Ischemia 01/2017 - 05/2006
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 06/2016 - 06/2005
3	Cardiac Arrhythmias (Arrythmia) 05/2014 - 01/2007
3	Bradycardia 12/2011 - 07/2005
3	Atherosclerotic Plaque (Atheroma) 07/2008 - 01/2002
3	Coronary Disease (Coronary Heart Disease) 05/2008 - 01/2002
3	Pre-Eclampsia (Preeclampsia) 04/2008 - 08/2002
3	Dyslipidemias (Dyslipidemia) 01/2004 - 01/2002
2	Chronic Renal Insufficiency 01/2020 - 09/2010
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 06/2005
2	Pathologic Processes 07/2016 - 01/2007
2	Albuminuria 03/2010 - 05/2009
2	Non-alcoholic Fatty Liver Disease 01/2009 - 09/2008
2	Neoplasms (Cancer) 03/2007 - 01/2007
2	Hyperlipidemias (Hyperlipidemia) 06/2005 - 01/2002

Drug/Important Bio-Agent (IBA)

44	Angiotensin IIIBA 04/2022 - 01/2002
21	ReninIBA 04/2022 - 01/2002
20	AngiotensinsIBA 04/2022 - 01/2002
19	angiotensin I (1-7)IBA 01/2020 - 04/2002
14	Peptides (Polypeptides)IBA 04/2022 - 01/2002
14	Chymases (Chymase)IBA 08/2020 - 01/2014
11	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 06/2002
11	Angiotensin Receptor AntagonistsIBA 09/2020 - 01/2002
10	Angiotensin-Converting Enzyme 2IBA 01/2021 - 06/2002
10	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 06/2004
9	AldosteroneIBA 04/2022 - 01/2012
9	Estrogens (Estrogen)FDA Link 01/2019 - 10/2002
9	SaltsIBA 01/2017 - 06/2002
9	NADPH Oxidases (NAD(P)H oxidase)IBA 06/2012 - 08/2007
8	Proteins (Proteins, Gene)FDA Link 10/2020 - 10/2002
8	olmesartanIBA 02/2013 - 10/2003
8	Insulin (Novolin)FDA Link 12/2011 - 02/2005
6	Estrogen ReceptorsIBA 11/2021 - 01/2017
6	Pharmaceutical PreparationsIBA 04/2021 - 10/2002
6	AngiotensinogenIBA 01/2021 - 11/2005
6	Nebivolol FDA Link 01/2014 - 01/2009
6	3-nitrotyrosineIBA 12/2013 - 07/2008
5	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2020 - 01/2002
5	EnzymesIBA 01/2012 - 06/2002
5	Glucose (Dextrose)FDA LinkGeneric 12/2011 - 02/2005
5	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2011 - 08/2007
4	GTP-Binding Proteins (G-Protein)IBA 11/2021 - 01/2017
4	Messenger RNA (mRNA)IBA 08/2020 - 03/2007
4	Oxidants (Oxidizing Agents)IBA 12/2013 - 03/2010
4	Type 1 Angiotensin ReceptorIBA 06/2013 - 10/2002
4	CollagenIBA 09/2012 - 07/2005
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2012 - 10/2002
4	Nitric Oxide Synthase (NO Synthase)IBA 06/2012 - 05/2008
4	Atenolol (Tenormin)FDA LinkGeneric 12/2011 - 11/2004
3	salicylhydroxamic acid (SHAM)IBA 01/2017 - 10/2003
3	Valsartan (Vals)FDA Link 01/2014 - 02/2005
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2009 - 01/2002
3	CholesterolIBA 09/2009 - 01/2002
3	Vasoconstrictor AgentsIBA 05/2008 - 01/2002
2	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 04/2021 - 03/2008
2	Hormones (Hormone)IBA 01/2020 - 01/2016
2	CalciumIBA 12/2019 - 01/2019
2	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2015 - 05/2009
2	Transforming Growth Factors (Transforming Growth Factor)IBA 04/2014 - 12/2013
2	BradykininIBA 01/2014 - 01/2012
2	Biomarkers (Surrogate Marker)IBA 12/2013 - 02/2013
2	CytokinesIBA 12/2013 - 10/2002
2	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 01/2012 - 01/2011
2	Cadherins (E-Cadherin)IBA 01/2012 - 01/2011
2	TOR Serine-Threonine KinasesIBA 01/2012 - 01/2011
2	Spironolactone (Aldactone)FDA LinkGeneric 01/2012 - 05/2009
2	Olmesartan Medoxomil (Votum)FDA Link 12/2011 - 01/2002
2	nephrinIBA 03/2010 - 05/2009
2	Oxidoreductases (Dehydrogenase)IBA 09/2009 - 01/2002
2	LipidsIBA 02/2009 - 01/2002
2	tempolIBA 09/2008 - 02/2005
2	A-factor (Streptomyces)IBA 07/2005 - 08/2002
2	Losartan (Cozaar)FDA LinkGeneric 11/2004 - 01/2002
2	omapatrilatIBA 10/2002 - 06/2002
1	Monoclonal AntibodiesIBA 01/2022
1	human angiotensin-(1-12)IBA 01/2022
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 04/2021

Therapy/Procedure

17	Therapeutics 04/2022 - 11/2002
2	Ligation 05/2004 - 10/2003